Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Feb 25

PMID 33628032

Citations 9

Authors

Yang Fu

Yue Zheng

Pei-Pei Wang

Yue-Yun Chen

Zhen-Yu Ding

Affiliations

Soon will be listed here.

Abstract

Background: Lymphoepithelioma-like carcinoma (LELC) is a rare malignant tumor of the lung. It is related to EB virus infection. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are rarely found in this disease, while high level programmed cell death ligand 1 (PD-L1) expression is observed. Here a series of patients with advanced LELC treated with immunotherapy were summarized.

Methods: This retrospective, observational study was conducted in patients who were pathologically confirmed, metastatic or recurrent LELC patients. Patients were prescribed with either chemotherapy or immunotherapy, according to treating physicians' discretion.

Results: A total of 27 patients were included in our study, 10 with immunotherapy (ICI group) and 17 with chemotherapy (Chemo group). The objective response rates (ORR) of the two groups were 80.0% and 70.5% (p=0.678), and disease control rates (DCR) were 100% and 88.2% (p=0.516). However, the response depth was better in the ICI group. Although the cohort of patients in the ICI group was in a disadvantageous state (both up-front and salvage), the progression-free survival (PFS) was much longer (15.0 and 7.9 m, p=0.005). The 1-year PFS rate in the ICI group was also much higher (40% and 5.9%, p=0.047).

Conclusion: This study implicated the high efficiency of ICI therapy in this disease.

Citing Articles

Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma-like carcinoma.

Zhong Y, Chen J, Jiang J, Zhou W, Gao L, Zhang S Clin Transl Immunology. 2024; 13(6):e1515.

PMID: 38835955 PMC: 11147665. DOI: 10.1002/cti2.1515.

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.

Tsai T, Su P, Huang S, Kuo M, Lin C, Wu C BMC Cancer. 2023; 23(1):871.

PMID: 37715113 PMC: 10504763. DOI: 10.1186/s12885-023-11398-w.

Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma.

Zhou N, Tang H, Yu S, Lin Y, Wang Y, Wang Y Front Immunol. 2022; 13:1001414.

PMID: 36561745 PMC: 9763302. DOI: 10.3389/fimmu.2022.1001414.

Epstein-Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments.

Shechter O, Sausen D, Gallo E, Dahari H, Borenstein R Int J Mol Sci. 2022; 23(22).

PMID: 36430864 PMC: 9699474. DOI: 10.3390/ijms232214389.

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.

Zhong Y, Yin K, Chen Y, Xie Z, Lv Z, Yang J Front Immunol. 2022; 13:951817.

PMID: 36263036 PMC: 9574915. DOI: 10.3389/fimmu.2022.951817.

References

Chang Y, Wu C, Shih J, Lee Y . New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol. 2002; 26(6):715-23. DOI: 10.1097/00000478-200206000-00004. View

Darrason M, Martin A, Soussan M, Chouahnia K, Pailler M, Boudabous H . Immunotherapy for LELC: Case Report and a Focused Review. Clin Lung Cancer. 2019; 20(3):e393-e401. DOI: 10.1016/j.cllc.2018.12.008. View

Wu Q, Wang W, Zhou P, Fu Y, Zhang Y, Shao Y . Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden. Pathol Res Pract. 2020; 216(8):153043. DOI: 10.1016/j.prp.2020.153043. View

Kang H, Oh J, Chun S, Kim D, Ryu Y, Hwang H . Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes. J Hepatol. 2019; 71(1):91-103. DOI: 10.1016/j.jhep.2019.03.018. View

Liu Q, Ma G, Yang H, Wen J, Li M, Yang H . Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma-like carcinoma of the lung. Thorac Cancer. 2016; 5(1):63-7. PMC: 4704286. DOI: 10.1111/1759-7714.12060. View

Xie Z, Liu L, Lin X, Xie X, Gu Y, Liu M . A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. Mod Pathol. 2019; 33(4):626-638. PMC: 7113185. DOI: 10.1038/s41379-019-0391-9. View

Chang Y, Wu C, Shih J, Lee Y . Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. Cancer Sci. 2010; 102(1):282-7. DOI: 10.1111/j.1349-7006.2010.01768.x. View

Xie M, Wu X, Wang F, Zhang J, Ben X, Zhang J . Clinical Significance of Plasma Epstein-Barr Virus DNA in Pulmonary Lymphoepithelioma-like Carcinoma (LELC) Patients. J Thorac Oncol. 2017; 13(2):218-227. DOI: 10.1016/j.jtho.2017.10.031. View

Lin C, Chen Y, Hsieh M, Wang C, Fang Y . Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome. J Thorac Dis. 2017; 9(1):123-128. PMC: 5303072. DOI: 10.21037/jtd.2017.01.25. View

10.

Tay C, Chua Y, Takano A, Chee M, Lim W, Lim C . Primary pulmonary lymphoepithelioma-like carcinoma in Singapore. Ann Thorac Med. 2018; 13(1):30-35. PMC: 5772105. DOI: 10.4103/atm.ATM_304_17. View

11.

Liang Y, Wang L, Zhu Y, Lin Y, Liu H, Rao H . Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up. Cancer. 2012; 118(19):4748-58. DOI: 10.1002/cncr.27452. View

12.

Qin Y, Gao G, Xie X, Zhu Z, Guan W, Lin X . Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-like Carcinoma: Summary of Eighty-five Cases. Clin Lung Cancer. 2019; 20(3):e329-e337. DOI: 10.1016/j.cllc.2018.12.014. View

13.

Chan A, Teo P, Lam K, Chan W, Chow J, Yim A . Multimodality treatment of primary lymphoepithelioma-like carcinoma of the lung. Cancer. 1998; 83(5):925-9. DOI: 10.1002/(sici)1097-0142(19980901)83:5<925::aid-cncr18>3.0.co;2-x. View

14.

Qiu Z, Zhou P, Wang K . Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report. Onco Targets Ther. 2019; 12:8595-8600. PMC: 6802557. DOI: 10.2147/OTT.S219512. View

15.

Hu Y, Ren S, Liu Y, Han W, Liu W . Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review. Onco Targets Ther. 2020; 13:3921-3929. PMC: 7227818. DOI: 10.2147/OTT.S241337. View

16.

Hong S, Liu D, Luo S, Fang W, Zhan J, Fu S . The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nat Commun. 2019; 10(1):3108. PMC: 6635366. DOI: 10.1038/s41467-019-10902-w. View

17.

Kim C, Rajan A, DeBrito P, Giaccone G . Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Transl Lung Cancer Res. 2017; 5(6):720-726. PMC: 5233874. DOI: 10.21037/tlcr.2016.11.06. View

18.

Chan J, Hui P, Tsang W, Law C, Ma C, Yip T . Primary lymphoepithelioma-like carcinoma of the lung. A clinicopathologic study of 11 cases. Cancer. 1995; 76(3):413-22. DOI: 10.1002/1097-0142(19950801)76:3<413::aid-cncr2820760311>3.0.co;2-x. View

19.

Kasai K, Kon S, Sato N, Muraishi K, Yoshida H, Nakai N . Case report of lymphoepithelioma-like carcinoma of the lung--lymphoid population consisting of cytotoxic T cells in resting state. Pathol Res Pract. 1999; 195(11):773-9. DOI: 10.1016/S0344-0338(99)80120-4. View

20.

Tang Z, Fang R, Tong G, Liu P, Ou Z, Tang Y . Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature. Lung Cancer. 2020; 146:335-340. DOI: 10.1016/j.lungcan.2020.06.027. View